Copyright
©The Author(s) 2019.
World J Gastroenterol. Aug 14, 2019; 25(30): 4172-4180
Published online Aug 14, 2019. doi: 10.3748/wjg.v25.i30.4172
Published online Aug 14, 2019. doi: 10.3748/wjg.v25.i30.4172
Disease | TC | LDL | HDL | TG | Phenotype |
LAL-related dyslipidemia | ↑↑↑ | ↑↑↑ | ↓ | ↑ | IIa, IIb, |
Familial hypercholesterolemia | ↑↑↑ | ↑↑↑ | =/↓ | = | IIa, IIb |
Familial combined hyperlipidemia | ↑↑ | ↑↑ | ↓ | ↑ | IIa, IIb, IV, V |
Familial hypertriglyceridemia | N/ | ↓ | ↓↓ | ↑↑ | IV, V |
Type III hyperlipidemia (dysbetalipoproteinemia) | ↑↑ | ↓ | = | ↑↑ | III, IV |
Iperchylomicronemia | ↑ | ↓ | ↓↓↓ | ↑↑↑ | I, V |
Hypoalfalipoproteinemia | N/↓ | N | ↓↓↓↓ | N | Low HDL |
- Citation: Baratta F, Pastori D, Ferro D, Carluccio G, Tozzi G, Angelico F, Violi F, Del Ben M. Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease? World J Gastroenterol 2019; 25(30): 4172-4180
- URL: https://www.wjgnet.com/1007-9327/full/v25/i30/4172.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i30.4172